Evergreen Select used to be called Omeat, which tells you everything about where this story starts and why it matters. In a market addicted to shiny slogans and lab-coated optimism, this company took...
Evergreen Select used to be called Omeat, which tells you everything about where this story starts and why it matters. In a market addicted to shiny slogans and lab-coated optimism, this company took a breath, changed the name on the door, and doubled down on something far more dangerous than hype: execution. The kind that survives market cycles, regulatory scrutiny, and dinner table conversations where people still ask uncomfortable questions about their food.
The headline is clean. Evergreen Select closed a $6M Series A extension, pushing total capital north of $55M+. S2G Investments leaned back in, BOLD Capital Partners stayed at the table, and Good Startup joined the conversation. That does not happen because a pitch deck had good vibes. It happens because the underlying thesis keeps holding up when adults start asking adult questions.
Jim Miller, President and CEO, is not guessing his way through scale. 30+ years across biopharma, healthcare manufacturing, and capital projects tends to sand the nonsense off a leader. Eric Schulze, PhD, Chief Scientific and Technology Officer, knows the regulatory maze from the inside, having helped secure the first FDA safety greenlight for cultivated meat before this role ever existed. Ali Khademhosseini, PhD, the founder, sits where founders should sit at this stage: guiding, advising, and letting the system work without ego getting in the way.
Evergreen Select is not chasing novelty. They are selling stability to an industry built on volatility. Their plasma-derived growth factors replace fetal bovine serum, harvested from living cows through plasmapheresis. No slaughter, no antibiotics, no genetic tricks, just more usable beef over time from the same animal. Plenty, their B2B cell culture supplement, has been generating revenue since 2023, quietly proving that cultivated meat infrastructure can pay rent before it becomes a dinner entrée.
The pilot plant outside Los Angeles is already pulling its weight. 15,000 square feet, bioreactors up to 10,000L, and capacity pushing 400 tons annually. This round is about regulatory due diligence, the unsexy work that separates science projects from supply chains. The strategy is partnership, not conquest, integrating with existing meat distributors and aiming for radical consistency in cost, taste, texture, and delivery.
There is a lesson here for founders watching from the sidelines. Rebrands are not cosmetic when they reflect strategic maturity. Capital follows clarity. Regulators respond to respect. Markets reward companies that stop trying to impress everyone and start serving the people who actually write checks, sign approvals, and move product.